-
TLI: Fueling Biomedical Innovation and Entrepreneurship
The Lundquist Institute translates scientific discoveries into innovations that enhance human health, benefiting our community and the world. This mission comes to life through a focused commitment to advancing research…
Innovation -
The Lundquist Institute and Its Start-Up Company Vitalex Biosciences Announce Strategic Advancement of Second-Generation Fungal Vaccine VXV-01 Through Phase 1 Trials Under $40 Million Competitive Contract From NIH/NIAID
The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) are pleased to announce that the second-generation fungal vaccine candidate known as VXV01, which was…
Innovation, Research -
TLI Receives $2.6 Million Grant from USAMRAA to Develop Wearable Biosensors
The proposed sensor has the potential to not only revolutionize COPD management but also to impact healthcare by incorporating wearable electronics into chronic disease management
Innovation, Research -
Lundquist Institute Investigator Dr. Frans Walther Receives Grant to Develop an Aerosolized Lung Surfactant
The non-invasive delivery device will be for use in respiratory distress syndrome (RDS), a significant cause of neonatal mortality and morbidity
Innovation, Research -
The Lundquist Institute Out-Licenses Development of a Synthetic Lung Surfactant Formulation
Bill & Melinda Gates Medical Research Institute To Develop Formulation -Agreement advances evolution of synthetic lung surfactants to treat respiratory distress Syndrome in premature infants in…
Innovation, Research -
Amgen Sponsors Golden Ticket at Biolabs LA at The Lundquist Institute to Help Accelerate Life Science Startups
Amgen Golden Ticket Winners to Receive Lab Space, Mentoring and Other Benefits
Innovation, Research -
The Lundquist Institute at Harbor-UCLA Medical Center Administers First Phase 3 AstraZeneca Trial Injection
First participants received the shot at The Lundquist Institute on Friday, September 4; more injections scheduled next week
Community, Innovation, Research -
Technologies First Created at The Lundquist Institute Achieve 3rd FDA Approval in 5 Years
Tepezza™ is first and only FDA-approved treatment for Thyroid Eye Disease. Approval marks fourth FDA-approved product containing technologies created at The Lundquist Institute.
Innovation, Research -
Omega-3 Drug Vascepa Slows Progress of Heart Disease, New Study from The Lundquist Institute Shows
The Lundquist Institute investigator Dr. Matthew Budoff presented results at AHA conference Study shows The Lundquist Institute is top-tier venue for pharmaceutical research
Innovation, Research -
Los Angeles’ Most Advanced Life Science Co-Working Space Opens for Business, Welcomes Eight Innovative Startups
The new biotech coworking space, BioLabs LA at The Lundquist, is ready to welcome innovative bioscience startups
Innovation, Research